USPTO serial 97205537
RCB
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- BUTLER, MIDGE
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with RCB?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Naira Simmons
Naira Simmons FisherBroyles, LLP32 School LnScarsdale, NY 10583UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Biological preparations for the treatment of cancer; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Anti-cancer preparations; Protein arrays for diagnosing cancer; Biological preparations for the assessment of recurrence of cancer; Pharmaceutical products for the assessment of a treatment of viral and infectious diseases, for the assessment of treatment of cancer; assessment for anti-cancer preparations; assessment of protein arrays for diagnosing cancer | ACTIVE | — |
| 010 | Medical apparatus or device for assessing the recurrence of cancer; Medical diagnostic apparatus for assessing and predicting recurrence of cancer cells incorporating recorded operating system software; Medical nanites for assessing and predicting the recurrence of cancer; Medical nanorobots for assessing and predicting recurrence of cancer; Medical microrobots for assessing and predicting recurrence of cancer after treatment | ACTIVE | — |
| 042 | Medical and scientific research in the field of assessing and predicting recurrence cancer after treatment and diagnosis; Medical research services in the field of assessing and predicting recurrence of cancer; Providing laboratory research services in the field of assessing and predicting effectiveness of treatment and diagnosis in gene expression, namely, cancer biology; Research and development of pharmaceuticals for the assessment and prediction of effectiveness of treatment of age-related diseases and cancer; Assessment and predictions of medical diagnosis and treatment of cancer; Providing information about medical research, predictions and assessments in the field of cancer | ACTIVE | — |
| 044 | Medical testing, prediction and assessment for diagnostic, prognosis and treatment purposes in the field of cancer research and disease classification; Providing medical, assessment and prediction information to medical professionals in the field of cancer and disease classification; Providing medical information, assessment and prediction to medical professionals on sensitivities of cancers to hormones and/or hormone therapies | ACTIVE | — |
| 045 | Providing a website via a global computer network featuring supportive personal stories on the subjects of health, cancer, cancer recovery and survival | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Delphi Diagnostics, Inc.
- Other trademarks owned by Delphi Diagnostics, Inc.
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Other trademarks in Class 045
- Similar marks named RCB
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 25, 2023 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Sep 25, 2023 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Feb 2, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 31, 2023 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jan 31, 2023 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jan 31, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 30, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jan 30, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 30, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Aug 23, 2022 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jun 28, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 28, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 8, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 25, 2022 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| May 20, 2022 | ALIE | ASSIGNED TO LIE | — |
| May 18, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 3, 2022 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| May 3, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 3, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 10, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 10, 2022 | NWAP | NEW APPLICATION ENTERED | — |